MedTrace Logo

Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity

NCT06771115 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2025-11-10

No results posted yet for this study

Summary

This is a study to understand if taking VTX3232 alone or in combination with semaglutide is safe in participants diagnosed with Obesity. Approximately 160 patients will take VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide.

This study consists of a 30-day Screening Period (to see if a participant qualifies for a study), a 12-week double-blind treatment period (a participant receives VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, or Placebo in combination with semaglutide), and a 30-day Follow-Up Period. The maximum duration of treatment will be approximately 12 weeks.

Conditions

Interventions

DRUG

VTX3232 Dose A

VTX3232 Dose A

DRUG

Placebo

Placebo

DRUG

VTX3232 Dose A in combination with semaglutide

VTX3232 Dose A in combination with semaglutide

DRUG

Placebo in combination with semaglutide

Placebo in combination with semaglutide

Sponsors & Collaborators

  • Zomagen Biosciences Ltd.

    lead INDUSTRY

Principal Investigators

  • Snehal Naik, PhD · Zomagen Biosciences Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-07
Primary Completion
2025-09-10
Completion
2025-09-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06771115 on ClinicalTrials.gov